🇺🇸 FDA
Patent

US 10137193

Methods for treating or preventing asthma by administering an IL-4R antagonist

granted A61KA61K2039/54A61K2039/545

Quick answer

US patent 10137193 (Methods for treating or preventing asthma by administering an IL-4R antagonist) held by REGENERON PHARMACEUTICALS, INC. expires Mon Nov 22 2038 00:00:00 GMT+0000 (Coordinated Universal Time). Status: granted.

Key facts

Applicant
REGENERON PHARMACEUTICALS, INC.
Grant date
Tue Nov 27 2018 00:00:00 GMT+0000 (Coordinated Universal Time)
Expiration
Mon Nov 22 2038 00:00:00 GMT+0000 (Coordinated Universal Time)
Claims
30
CPC classes
A61K, A61K2039/54, A61K2039/545, A61K31/00, A61K31/137